Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | VDR | P11473 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058819 | 1.00 | CDC25A (0.49) | CDC25APOLA1CYP2D6CYP2C19VDR | |
| SCHEMBL2059340 | 0.83 | EBP (0.48) | CDC25APOLA1CYP2D6CYP2C19VDR | |
| SCHEMBL2059335 | 0.83 | EBP (0.48) | CDC25APOLA1CYP2D6CYP2C19VDR | |
| SCHEMBL2059168 | 0.82 | CDC25A (0.52) | CDC25APOLA1CYP2D6CYP2C19VDR | |
| SCHEMBL2059165 | 0.82 | CDC25A (0.52) | CDC25APOLA1CYP2D6CYP2C19VDR | |
| SCHEMBL12590996 | 0.76 | HPSE (0.59) | CDC25APOLA1HPSE | |
| SCHEMBL2058821 | 0.76 | HPSE (0.59) | CDC25APOLA1HPSE | |
| SCHEMBL24403430 | 0.74 | VDR (0.79) | CDC25APOLA1CYP2D6CYP2C19VDR | |
| SCHEMBL13214256 | 0.74 | VDR (0.79) | CDC25APOLA1CYP2D6CYP2C19VDR | |
| SCHEMBL11371121 | 0.74 | VDR (0.79) | CDC25APOLA1CYP2D6CYP2C19VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921086-B1 | ANTITUMOR AGENT | OTSUKA PHARMA CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-7968116-B2 | Antitumor agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20100292176-A1 | ANTITUMOR AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-1921086-A1 | ANTITUMOR AGENT | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292176-A1 | ANTITUMOR AGENT | CYP46A1, CETP, GYS2 | CDC25A 731/4885POLA1 1501/4885CYP2D6 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.